Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Q3 Losses Up as R&D Costs Increase


Alnylam Pharmaceuticals this week reported a rise in its third-quarter losses as spending increased on its research and development efforts and it paid severance associated with a recent restructuring.

For the three-month period ended Sept. 30, Alnylam's net loss climbed to $9.6 million, or $0.23 per share, from $9.2 million, or $0.22 per share, in the same period a year earlier.

R&D costs jumped to $27.5 million from $23.2 million, in part reflecting employee severance, benefits, and related costs tied to Alnylam's cutting around a quarter of its workforce following the end of its longstanding alliance with Novartis (GSN 9/30/2010).

An increasing in clinical trial and manufacturing costs also drove up the R&D expenses.

General and administrative costs slipped to $8.9 million from $10.7 million in the third quarter of last year, while third-quarter revenues increased to $27.7 million from $24.2 million.

As of Sept. 30, Alnylam had cash, cash equivalents, and marketable securities totaling $371.9 million. The company said it expects its cash balance at the end of 2010 to be more than $325 million.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.